DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Cancer, Genetic Disorders, Infectious Diseases, CVD, Neuro Disorders), By Vector Type (Viral, Non-Viral), By Region, and Segment Forecasts, 2018 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global gene therapy market size is expected to reach USD 39.54 million by 2026. Rising competition among manufacturers and high number of molecules in pipeline are supporting the growth of the market.

Gene therapy development is aimed to cure rare diseases and even some hereditary diseases, which are caused by a mutated or faulty gene. Moreover, ever-increasing need for new cures for orphan diseases and rising incidence of cancer caused due to mutations in genes are likely to stir up the demand for gene therapy.

As of early 2016, there were more than 1000 molecules in the pipeline in various clinical phases. However, around 76.0% of the molecules are in the developmental or preclinical stages and expected to hit the market in late 2020's.

A great number of large pharma/biotech players are estimated to acquire small firms as many have been trying to develop in-house expertise and build their own pipelines. This trend is anticipated to help the market gain tremendous traction over the coming years. Combination of gene therapy with small molecules or protein therapy is said to have lesser side effects and better efficacy as compared to gene therapy alone.

Cancer held the dominant share in the market in 2017 owing to relatively high adoption of gene therapies for cancer treatment.

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Gene Therapy Market: Indication Type Estimates & Trend Analysis

Chapter 5 Gene Therapy Market: Vector type Estimates & Trend Analysis

Chapter 6 Gene Therapy Market: Regional Estimates & Trend Analysis, by Indications Type and Component Type

Chapter 7 Competitive Landscape

UniQure N.V Spark Therapeutics LLC Bluebird Bio Celgene Corporation GlaxoSmithKline plc. Shire Plc. Cellectis Sangamo Biosciences Inc., ReGenX Bio. Inc., Oxford Biomedica Plc. Voyager Therapeutics Human Stem Cells Institute. Dimension Therapeutics Inc. Bristol Myers Squibb. Sanofi Genzyme. Applied Genetic Technologies Corporation. Chiesi Farmaceutici S.p.A Benitec BioPharma Sibiono GeneTech Co. Ltd Shanghai Sunway Biotech Co. Ltd Gensight Biologics S.A Transgene S.A Epeius Biotechnologies Corp Calimmune Inc. American Gene Technologies Juno Therapeutics, Inc. Biomarin Pharmaceuticals, Inc. TaxusCardium Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/research/8335pq/2018_gene_therapy?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005164/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/24/2018 08:08 AM/DISC: 08/24/2018 08:08 AM

http://www.businesswire.com/news/home/20180824005164/en